@article{b1403ad71dc94160bf0e4b4310ea9e8b,
title = "Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trial: Journal of Clinical Oncology",
abstract = "PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial (SOLO3) of olaparib tablets versus nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy. PATIENTS AND METHODS In this randomized, open-label trial, patients were randomly assigned 2:1 to olaparib 300 mg twice a day or physician{\textquoteright}s choice single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan). The primary end point was objective response rate (ORR) in the measurable disease analysis set assessed by blinded independent central review (BICR). The key secondary end point was progression-free survival (PFS) assessed by BICR in the intent-to-treat population. RESULTS Of 266 randomly assigned patients, 178 were assigned to olaparib and 88 to chemotherapy. In patients with measurable disease (olaparib, n = 151; chemotherapy, n = 72), the BICR-assessed ORR was significantly higher with olaparib than with chemotherapy (72.2% v 51.4%; odds ratio [OR], 2.53 [95% CI, 1.40 to 4.58]; P = .002). In the subgroup who had received 2 prior lines of treatment, the ORR was 84.6% with olaparib and 61.5% with chemotherapy (OR, 3.44 [95% CI, 1.42 to 8.54]). BICR-assessed PFS also significantly favored olaparib versus chemotherapy (hazard ratio, 0.62 [95% CI, 0.43 to 0.91]; P = .013; median, 13.4 v 9.2 months). Adverse events were consistent with the established safety profiles of olaparib and chemotherapy. CONCLUSION Olaparib resulted in statistically significant and clinically relevant improvements in ORR and PFS compared with nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy. Copyright {\textcopyright} 2020 American Society of Clinical Oncology. All rights reserved.",
keywords = "antineoplastic metal complex, BRCA1 protein, BRCA2 protein, doxorubicin, gemcitabine, olaparib, paclitaxel, topotecan, antineoplastic agent, phthalazine derivative, piperazine derivative, platinum derivative, abdominal pain, acute myeloid leukemia, adult, aged, alopecia, anemia, Article, asthenia, cancer chemotherapy, cancer patient, cancer recurrence, carcinogenesis, cardiopulmonary insufficiency, constipation, controlled study, diarrhea, drug dose reduction, drug safety, drug sensitivity, drug withdrawal, female, germline mutation, hand foot syndrome, human, major clinical study, mesenteric vein thrombosis, monotherapy, multicenter study, myelodysplastic syndrome, nausea, neutropenia, open study, ovary cancer, phase 3 clinical trial, primary tumor, priority journal, progression free survival, randomized controlled trial, sepsis, stomatitis, subarachnoid hemorrhage, thrombocytopenia, treatment duration, treatment response, vomiting, clinical trial, comparative study, genetics, middle aged, mortality, ovary tumor, tumor recurrence, tumor suppressor gene, very elderly, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Genes, BRCA1, Genes, BRCA2, Germ-Line Mutation, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Phthalazines, Piperazines, Platinum Compounds",
author = "R.T. Penson and R.V. Valencia and D. Cibula and N. Colombo and {Leath C.A.}, III and M. Bidzinski and J.-W. Kim and J.H. Nam and R. Madry and C. Hern{\'a}ndez and P.A.R. Mora and S.Y. Ryu and T. Milenkova and E.S. Lowe and L. Barker and G. Scambia",
note = "Cited By :28 Export Date: 4 March 2021 CODEN: JCOND Correspondence Address: Penson, R.T.; Harvard Medical School, 55 Fruit St, United States; email: penson.richard@mgh.harvard.edu Chemicals/CAS: doxorubicin, 23214-92-8, 25316-40-9; gemcitabine, 103882-84-4; olaparib, 763113-22-0; paclitaxel, 33069-62-4; topotecan, 119413-54-6, 123948-87-8; olaparib; Phthalazines; Piperazines; Platinum Compounds Funding details: AstraZeneca Funding details: Meso Scale Diagnostics, MSD Funding text 1: This study is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp (MSD), a subsidiary of Merck & Co, Kenilworth, NJ. We thank all the women who participated in this study, their families, and the investigators, and Teodora Goranova (AstraZeneca) for her contribution to the provision of the BRCA data. Medical writing assistance was provided by Gillian Keating, MBChB, from Mudskipper Business, funded by AstraZeneca and MSD. References: O{\textquoteright}Connor, M.J., Targeting the DNA damage response in cancer (2015) Mol Cell, 60, pp. 547-560; Matulonis, U.A., Penson, R.T., Domchek, S.M., Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety (2016) Ann Oncol, 27, pp. 1013-1019; Fong, P.C., Boss, D.S., Yap, T.A., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers (2009) N Engl J Med, 361, pp. 123-134; Fong, P.C., Yap, T.A., Boss, D.S., Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval (2010) J Clin Oncol, 28, pp. 2512-2519; Mateo, J., Moreno, V., Gupta, A., An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib (2016) Target Oncol, 11, pp. 401-415; Audeh, M.W., Carmichael, J., Penson, R.T., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial (2010) Lancet, 376, pp. 245-251; Kaye, S.B., Lubinski, J., Matulonis, U., Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (2012) J Clin Oncol, 30, pp. 372-379; Gelmon, K.A., Tischkowitz, M., Mackay, H., Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study (2011) Lancet Oncol, 12, pp. 852-861; Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation (2015) J Clin Oncol, 33, pp. 244-250; Highlights of Prescribing Information: LYNPARZA (Olaparib) Tablets, for Oral Use, , https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf; Bruchim, I., Jarchowsky-Dolberg, O., Fishman, A., Advanced (.second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer (2013) Eur J Obstet Gynecol Reprod Biol, 166, pp. 94-98; Hanker, L.C., Loibl, S., Burchardi, N., The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy (2012) Ann Oncol, 23, pp. 2605-2612; Gordon, A.N., Fleagle, J.T., Guthrie, D., Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan (2001) J Clin Oncol, 19, pp. 3312-3322; Global Policy: Bioethics, , https://www.astrazeneca.com/content/dam/az/PDF/Sustainability/code-of-ethics-2018/AZ%20Code%20of%20Ethics%20-%20English.pdf; Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M.A., Reliability and validity of the functional assessment of cancer therapy-ovarian (2001) J Clin Oncol, 19, pp. 1809-1817; Osoba, D., Bezjak, A., Brundage, M., Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group (2005) Eur J Cancer, 41, pp. 280-287; Villalobos, V.M., Wang, Y.C., Sikic, B.I., Reannotation and analysis of clinical and chemotherapy outcomes in the ovarian data set from the Cancer Genome Atlas (2018) JCO Clin Cancer Inform, 2, pp. 1-16; Domchek, S.M., Mitchell, G., Lindeman, G.J., Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer (2011) J Clin Oncol, 29, pp. 4224-4226; Oza, A.M., Tinker, A.V., Oaknin, A., Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 (2017) Gynecol Oncol, 147, pp. 267-275; Kristeleit, R., Shapiro, G.I., Burris, H.A., A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors (2017) Clin Cancer Res, 23, pp. 4095-4106; Swisher, E.M., Lin, K.K., Oza, A.M., Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial (2017) Lancet Oncol, 18, pp. 75-87; Moore, K.N., Secord, A.A., Geller, M.A., Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial (2019) Lancet Oncol, 20, pp. 636-648; Moore, K., Colombo, N., Scambia, G., Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (2018) N Engl J Med, 379, pp. 2495-2505; Pujade-Lauraine, E., Ledermann, J.A., Selle, F., Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial (2017) Lancet Oncol, 18, pp. 1274-1284; Ledermann, J., Harter, P., Gourley, C., Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (2014) Lancet Oncol, 15, pp. 852-861; Friedlander, M., Matulonis, U., Gourley, C., Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (2018) Br J Cancer, 119, pp. 1075-1085; Mutch, D.G., Orlando, M., Goss, T., Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer (2007) J Clin Oncol, 25, pp. 2811-2818; ten Bokkel Huinink, W., Gore, M., Carmichael, J., Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer (1997) J Clin Oncol, 15, pp. 2183-2193; Morton, L.M., Dores, G.M., Schonfeld, S.J., Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era (2019) JAMA Oncol, 5, pp. 318-325; Ledermann, J.A., Harter, P., Gourley, C., Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial (2016) Lancet Oncol, 17, pp. 1579-1589; Coleman, R.L., Oza, A.M., Lorusso, D., Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial (2017) Lancet, 390, pp. 1949-1961; Mirza, M.R., Monk, B.J., Herrstedt, J., Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer (2016) N Engl J Med, 375, pp. 2154-2164",
year = "2020",
doi = "10.1200/JCO.19.02745",
language = "English",
volume = "38",
pages = "1164--1174",
journal = "J. Clin. Oncol.",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",
}